Medline (NASDAQ:MDLN – Get Free Report) had its price target lowered by equities research analysts at BNP Paribas Exane from $49.00 to $40.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the stock. BNP Paribas Exane’s price objective indicates a potential upside of 2.85% from the stock’s current price.
MDLN has been the subject of several other reports. Evercore restated an “outperform” rating and issued a $55.00 target price on shares of Medline in a research note on Wednesday, February 25th. BTIG Research restated a “buy” rating and issued a $55.00 target price on shares of Medline in a research note on Thursday, May 7th. JPMorgan Chase & Co. upped their target price on shares of Medline from $50.00 to $53.00 and gave the company an “overweight” rating in a research note on Tuesday, March 10th. Stifel Nicolaus set a $55.00 target price on shares of Medline in a research note on Wednesday, February 25th. Finally, Deutsche Bank Aktiengesellschaft set a $42.00 target price on shares of Medline in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $50.85.
Get Our Latest Analysis on Medline
Medline Stock Performance
Medline (NASDAQ:MDLN – Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.04. The firm had revenue of $7.35 billion during the quarter. The firm’s quarterly revenue was up 10.7% compared to the same quarter last year. As a group, equities analysts forecast that Medline will post 1.5 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in MDLN. Carlyle Group Inc. bought a new position in shares of Medline in the 4th quarter worth about $9,042,728,000. H&F Corporate Investors X Ltd. bought a new position in shares of Medline in the 4th quarter worth about $4,179,591,000. Vanguard Group Inc. bought a new position in shares of Medline in the 4th quarter worth about $793,278,000. Morgan Stanley bought a new position in shares of Medline in the 4th quarter worth about $636,807,000. Finally, Capital Research Global Investors bought a new position in shares of Medline in the 4th quarter worth about $620,937,000.
Medline Company Profile
Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.
In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.
See Also
- Five stocks we like better than Medline
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.
